ClinicalTrials.gg
RecruitingNCT06674785Updated Jul 29, 2025

SIRS-ESWT Trial: Shoulder Internal Rotator Spasticity Trial Treated With Extracorporeal Shock Wave Therapy Trial

An interventional study of focused extracorporeal shock wave therapy (ESWT) and focused extracorporeal shock wave therapy (ESWT) in Stroke and Muscle Spasticity, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-29.

Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 77 studies in Stroke by National Taiwan University Hospital — 21 open to participants now, 22 under way, none of them phase 3. Stroke · National Taiwan University Hospital.

Planned enrollment
36th of 52
40 · median 70
Started
2025
with 4 others
No phase
43 of 77
17 open now
Primary completion
2026-12
later than 9 of 21 live
Registered
70th of 77
by date

Among the 77 studies in Stroke by National Taiwan University Hospital, this one is the 36th largest by planned enrollment of the 52 interventional ones that give a count, is one of 5 that started in 2025, is one of 43 with no phase, reaches primary completion later than 9 of the 21 other live ones, and was the 70th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

21 of the 77 studies in Stroke by National Taiwan University Hospital are open now, in 1 country. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 21 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Stroke by National Taiwan University Hospital, or all of them as a file.
02

Study summary

Extracorporeal shock wave therapy (ESWT) has shown potential in reducing post-stroke limb spasticity. This study aims to evaluate the efficacy of focused ESWT on shoulder internal rotator spasticity in post-stroke patients.

Read the detailed description

This study aimed to evaluate the effects of focused extracorporeal shock wave therapy (ESWT) on shoulder internal rotator spasticity in stroke patients. Participants were randomized into two groups: an experimental group receiving targeted ESWT on specific shoulder internal rotators, and a control group receiving placebo treatments mimicking the shockwave therapy, with treatments administered twice weekly over two weeks for a total of four sessions.

The efficacy of the treatment was measured using a comprehensive set of assessment tools, including range of motion, pain levels, spasticity scales, functional assessments, as well as measures of daily living activities, and ultrasound strain elastography. The outcomes were evaluated at multiple points in time: before treatment, and 1, 4, 12, and 24 weeks after the therapy concluded, to assess both immediate and sustained effects of the treatment on shoulder function and spasticity in stroke survivors.

03

Conditions studied

  • Stroke
  • Muscle Spasticity

Keywords

  • stroke
  • spasticity
  • shock wave
  • shoulder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 years or older with unilateral cerebral stroke.
  • Restricted passive external rotation of the spastic shoulder by more than 20 degrees.
  • A Modified Ashworth Scale score of 1 or higher for shoulder internal rotator spasticity.
  • Stable medical condition and vital signs.
  • Clear consciousness, able to follow instructions.

Exclusion criteria

Exclusion Criteria:

  • History of two or more strokes, traumatic brain injury, brain tumors, or other cerebral disorders.
  • Coexisting central nervous system disorders (e.g., spinal cord injury, Parkinson's disease) or other musculoskeletal conditions affecting muscle tone assessment.
  • Ineligibility for shock wave intervention due to , coagulation disorders, localized infections, or presence of a pacemaker.
  • Prior shock wave intervention or botulinum toxin injection for post-stroke spasticity within the past three months.
  • Inability to participate in interventions or functional assessments due to cognitive, consciousness, or language impairments.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Focused Extracorporeal Shock Wave

    Participants in this arm will receive focused Extracorporeal Shock Wave Therapy (ESWT) targeting four specific muscles: subscapularis, pectoralis major, latissimus dorsi, and teres major muscles. Each muscle will receive 1,000 shockwave shots per session, accumulating to a total of 4,000 shots across all targeted muscles in each session. The treatment will be administered twice a week for two consecutive weeks, resulting in a total of four treatment sessions.

    Device: focused extracorporeal shock wave therapy (ESWT)

  • Placebo comparator
    Placebo-Controlled Shockwave Therapy

    Participants in this arm will receive placebo-controlled focused ESWT, mirroring the treatment protocol of the experimental group but without the application of active shockwaves.

    Device: focused extracorporeal shock wave therapy (ESWT)

Interventions

  • Devicefocused extracorporeal shock wave therapy (ESWT)

    The focused shockwaves are directed at the affected muscles in the upper limb, specifically targeting the subscapularis, pectoralis major, latissimus dorsi, and teres major muscles.

  • Devicefocused extracorporeal shock wave therapy (ESWT)

    Placebo shockwave therapy directed at subscapularis, pectoralis major, latissimus dorsi, and teres major muscles.

06

What researchers measure

Primary outcomes

  1. passive range of motion for the shoulder joints

    the extent to which a joint can be moved without the patient actively participating in the movement

    Time frame: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

  2. shoulder strength

    the muscle power generated by the shoulder muscles, quantified using the Medical Research Council (MRC) scale, which grades muscle strength from 0 (no visible contraction) to 5 (normal strength against full resistance)

    Time frame: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

  3. Visual Analogue Scale (VAS)

    individuals rate their pain from 0 to 10, where 0 represents 'no pain' and 10 signifies 'the worst pain imaginable

    Time frame: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

  4. modified Ashworth scale (MAS)

    Evaluate spasticity in individuals with neurological conditions. The scale ranges from 0, indicating no increase in muscle tone, to 4, which represents severe spasticity with affected parts rigid in flexion or extension.

    Time frame: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

Secondary outcomes

  1. Fugl-Meyer Assessment for the Upper Extremity (FMA-UE)

    range from 0 (complete paralysis) to 66 (full function), assessing motor recovery in post-stroke upper extremities

    Time frame: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

  2. Action Research Arm Test (ARAT)

    a standardized measure evaluating upper limb motor ability in stroke patients, scoring from 0 (no movement) to 57 (normal arm function). It assesses grasp, grip, pinch, and gross arm movement.

    Time frame: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

  3. Barthel index

    measures a person's daily living abilities, focusing on ten areas of self-care and mobility. Scores range from 0 to 100, with higher scores denoting greater independence.

    Time frame: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

  4. Wolf Motor Function Test

    assess upper extremity function in individuals with neurological impairments, using 17 tasks divided into sections of time, functional ability, and strength. Scoring is on a 6-point ordinal scale, ranging from 0 ("Does not attempt with upper extremity being tested," indicating severe impairment) to 5 ("Movement appears to be normal," suggesting full functionality). Lower scores indicate greater impairment.

    Time frame: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

  5. ultrasound assessment

    used strain elastography to assess elasticity of shoulder muscles

    Time frame: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Haghighat S, Khosravi M, Saadatnia M, Hashemijaazi M. Effect of Extracorporeal Shockwave Therapy on Pain Management of Patients with Post-Stroke Hemiplegic Shoulder Pain: A Prospective Randomized Controlled Trial. Adv Biomed Res. 2023 Aug 31;12:216. doi: 10.4103/abr.abr_279_21. eCollection 2023. PubMed 38073721 ↗
  • Wu YT, Chang CN, Chen YM, Hu GC. Comparison of the effect of focused and radial extracorporeal shock waves on spastic equinus in patients with stroke: a randomized controlled trial. Eur J Phys Rehabil Med. 2018 Aug;54(4):518-525. doi: 10.23736/S1973-9087.17.04801-8. Epub 2017 Oct 25. PubMed 29072044 ↗
  • Yoon SH, Shin MK, Choi EJ, Kang HJ. Effective Site for the Application of Extracorporeal Shock-Wave Therapy on Spasticity in Chronic Stroke: Muscle Belly or Myotendinous Junction. Ann Rehabil Med. 2017 Aug;41(4):547-555. doi: 10.5535/arm.2017.41.4.547. Epub 2017 Aug 31. PubMed 28971038 ↗
  • Li G, Yuan W, Liu G, Qiao L, Zhang Y, Wang Y, Wang W, Zhao M, Wang Y, Wang J. Effects of radial extracorporeal shockwave therapy on spasticity of upper-limb agonist/antagonist muscles in patients affected by stroke: a randomized, single-blind clinical trial. Age Ageing. 2020 Feb 27;49(2):246-252. doi: 10.1093/ageing/afz159. PubMed 31846499 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 17 months is below that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2024
First posted
Nov 5, 2024
StartActual
Jul 23, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Jul 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06674785
Responsible party
Sponsor
First posted
Nov 5, 2024
Start date
Jul 23, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jul 29, 2025

Study contacts

Shu-mei Yang, MD
Contact
b99401109@gmail.com
0972653675
Shu-mei Yang, MD
principal investigator · National Taiwan University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion